Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Obstructive Lung Diseases

  Free Subscription

Articles published in Respir Med

Retrieve available abstracts of 200 articles:
HTML format

Single Articles

    August 2022
  1. SOUTO-MIRANDA S, Antao J, Rodrigues G, Mendes MA, et al
    Cut-off of the one-minute sit-to-stand test to detect functional impairment in people with chronic obstructive pulmonary disease.
    Respir Med. 2022;199:106892.
    PubMed     Abstract available

    July 2022
  2. DALIN DA, Lokke A, Kristiansen P, Jensen C, et al
    A systematic review of blood eosinophils and continued treatment with inhaled corticosteroids in patients with COPD.
    Respir Med. 2022;198:106880.
    PubMed     Abstract available

  3. YOHANNES AM, Murri MB, Hanania NA, Regan EA, et al
    Depressive and anxiety symptoms in patients with COPD: A network analysis.
    Respir Med. 2022;198:106865.
    PubMed     Abstract available

  4. AL CHIKHANIE Y, Bailly S, Amroussa I, Veale D, et al
    Clustering of COPD patients and their response to pulmonary rehabilitation.
    Respir Med. 2022;198:106861.
    PubMed     Abstract available

  5. ZAFARI Z, Lee TY, Sadatsafavi M
    External validation of lung function predictions in real-world cohorts of COPD.
    Respir Med. 2022;198:106859.
    PubMed     Abstract available

    June 2022
  6. LUOTO J, Pihlsgard M, Pistolesi M, Paoletti M, et al
    Emphysema severity index (ESI) associated with respiratory death in a large Swedish general population.
    Respir Med. 2022;200:106899.
    PubMed     Abstract available

  7. LEONARD SI, Turi ER, Powell JS, Usseglio J, et al
    Associations of asthma self-management and mental health in adolescents: A scoping review.
    Respir Med. 2022;200:106897.
    PubMed     Abstract available

  8. SINGH D, Rabe KF, Martinez FJ, Krull M, et al
    Relationship between prior inhaled corticosteroid use and benefits ofbudesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary d
    Respir Med. 2022;197:106857.
    PubMed     Abstract available

  9. BRUSSE-KEIZER M, Citgez E, Zuur-Telgen M, Kerstjens HAM, et al
    Difference in survival between COPD patients with an impaired immune reaction versus an adequate immune reaction to seasonal influenza vaccination: The COMIC study.
    Respir Med. 2022;197:106851.
    PubMed     Abstract available

  10. SULKU J, Janson C, Melhus H, Stallberg B, et al
    Changes in critical inhaler technique errors in inhaled COPD treatment - A one-year follow-up study in Sweden.
    Respir Med. 2022;197:106849.
    PubMed     Abstract available

  11. COLAK Y, Nordestgaard BG, Vestbo J, Afzal S, et al
    Potential clinical implications of targeted spirometry for detection of COPD: A contemporary population-based cohort study.
    Respir Med. 2022;197:106852.
    PubMed     Abstract available

  12. DA LUZ GOULART C, Oliveira MR, Sendin FA, Mendes RG, et al
    Prognostic value of key variables from cardiopulmonary exercise testing in patients with COPD: 42-month follow-up.
    Respir Med. 2022;197:106856.
    PubMed     Abstract available

  13. MANNINO D, Bogart M, Wu B, Germain G, et al
    Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study.
    Respir Med. 2022;197:106807.
    PubMed     Abstract available

  14. YOHANNES AM, Casaburi R, Dryden S, Hanania NA, et al
    The effectiveness of pulmonary rehabilitation on chronic obstructive pulmonary disease patients with concurrent presence of comorbid depression and anxiety.
    Respir Med. 2022;197:106850.
    PubMed     Abstract available

    May 2022
  15. SON JH, Park JS, Lee JU, Kim MK, et al
    A genome-wide association study on frequent exacerbation of asthma depending on smoking status.
    Respir Med. 2022 May 17:106877. doi: 10.1016/j.rmed.2022.106877.
    PubMed     Abstract available

  16. IKWU I, Nicolas LG, Mehari A, Gillum RF, et al
    Fractional exhaled nitric oxide and mortality in asthma and chronic obstructive pulmonary disease in a national cohort aged 40 years and older.
    Respir Med. 2022 May 16:106879. doi: 10.1016/j.rmed.2022.106879.
    PubMed     Abstract available

  17. JIAO T, Schnitzer ME, Forget A, Blais L, et al
    Identifying asthma patients at high risk of exacerbation in a routine visit: A machine learning model.
    Respir Med. 2022;198:106866.
    PubMed     Abstract available

  18. SIRAJ RA, McKeever TM, Gibson JE, Bolton CE, et al
    Incidence of depression and antidepressant prescription in patients with COPD: A large UK population-based cohort study.
    Respir Med. 2022;196:106804.
    PubMed     Abstract available

  19. HARTMAN JE, Welling JBA, Klooster K, Carpaij OA, et al
    Survival in COPD patients treated with bronchoscopic lung volume reduction.
    Respir Med. 2022;196:106825.
    PubMed     Abstract available

  20. HESSE K, Bourke S, Steer J
    Heart failure in patients with COPD exacerbations: Looking below the tip of the iceberg.
    Respir Med. 2022;196:106800.
    PubMed     Abstract available

    April 2022
  21. CHIU YC, Chang WP, Tang GJ, Lan TY, et al
    Chronic obstructive pulmonary disease is associated with a higher risk of functional gastrointestinal disorders.
    Respir Med. 2022;197:106833.
    PubMed     Abstract available

  22. OBLING N, Backer V, Hurst JR, Bodtger U, et al
    Nasal and systemic inflammation in Chronic Obstructive Pulmonary Disease (COPD).
    Respir Med. 2022;195:106774.
    PubMed     Abstract available

  23. MACDONALD DM, Palzer EF, Abbasi A, Baldomero AK, et al
    Chronotropic index during 6-minute walk and acute respiratory events in COPDGene.
    Respir Med. 2022;194:106775.
    PubMed     Abstract available

    March 2022
  24. KORN S, Milger K, Skowasch D, Timmermann H, et al
    Corrigendum to "The German severe asthma patient: Baseline characteristics of patients in the German Severe Asthma Registry, and relationship with exacerbations and control" [Respir. Med. 195 (2022) 106793].
    Respir Med. 2022;196:106827.

  25. RILEY L, Lascano J
    Labelling Alpha-1 antitrypsin deficiency in the medical record - A call to action.
    Respir Med. 2022;193:106749.
    PubMed     Abstract available

  26. YOHANNES AM, Casaburi R, Dryden S, Hanania NA, et al
    Predictors of premature discontinuation and prevalence of dropouts from a pulmonary rehabilitation program in patients with chronic obstructive pulmonary disease.
    Respir Med. 2022;193:106742.
    PubMed     Abstract available

  27. PHILLIPS TM, Moloney C, Sneath E, Beccaria G, et al
    Associated factors, assessment, management, and outcomes of patients who present to the emergency department for acute exacerbation of chronic obstructive pulmonary disease: A scoping review.
    Respir Med. 2022;193:106747.
    PubMed     Abstract available

    February 2022
  28. KORN S, Milger K, Skowasch D, Timmermann H, et al
    The German severe asthma patient: Baseline characteristics of patients in the German Severe Asthma Registry, and relationship with exacerbations and control.
    Respir Med. 2022;195:106793.
    PubMed     Abstract available

  29. BENDIEN SA, van Leeuwen MM, Lau HS, Ten Brinke A, et al
    Home-based intravenous treatment with reslizumab for severe asthma in the Netherlands - An evaluation.
    Respir Med. 2022 Feb 23:106776. doi: 10.1016/j.rmed.2022.106776.
    PubMed     Abstract available

  30. AL-AHMAD M, Webb D
    A prospective study of switching asthma patients from a Fixed-Dose Combination (FDC) Inhaled Corticosteroid [ICS]/Long-Acting Beta Agonist [LABA] therapy delivered by Dry Powder Inhaler (DPI) to ICS/LABA delivered by pressurised Metered Dose Inhaler (
    Respir Med. 2022;194:106771.
    PubMed     Abstract available

  31. ABOZID H, Baxter CA, Hartl S, Braun E, et al
    Distribution of chronic cough phenotypes in the general population: A cross-sectional analysis of the LEAD cohort in Austria.
    Respir Med. 2022;192:106726.
    PubMed     Abstract available

  32. MAROTT JL, Colak Y, Ingebrigtsen TS, Vestbo J, et al
    Exacerbation history, severity of dyspnoea and maintenance treatment predicts risk of future exacerbations in patients with COPD in the general population.
    Respir Med. 2022;192:106725.
    PubMed     Abstract available

    January 2022
  33. JI Z, Lopez-de-Andres A, Jimenez-Garcia R, Maestre-Miquel C, et al
    Mental health in patients with asthma: A population-based case-control study.
    Respir Med. 2022;193:106758.
    PubMed     Abstract available

  34. VRSALOVIC R, Korosec P, Stefanovic IM, Bidovec-Stojkovic U, et al
    Value of thymic stromal lymphopoietin as a biomarker in children with asthma.
    Respir Med. 2022;193:106757.
    PubMed     Abstract available

  35. METERSKY ML, Choate R, Aksamit TR, Conrad D, et al
    Stenotrophomonas maltophilia in patients with bronchiectasis: An analysis of the US bronchiectasis and NTM Research Registry.
    Respir Med. 2022;193:106746.
    PubMed     Abstract available

  36. TAKASAKA N, Hosaka Y, Fukuda T, Shinfuku K, et al
    Impact of emphysema on the prognosis of Mycobacterium avium complex pulmonary disease.
    Respir Med. 2022;192:106738.
    PubMed     Abstract available

  37. ELBORN JS, Blasi F, Haworth CS, Ballmann M, et al
    Bronchiectasis and inhaled tobramycin: A literature review.
    Respir Med. 2022;192:106728.
    PubMed     Abstract available

  38. BOURDIN A, Molinari N
    Non-optimal methodology questions indirect treatment comparison of dupilumab vs. other biologics in severe asthma.
    Respir Med. 2022;191:105999.

  39. BATEMAN ED, Khan AH, Xu Y, Guyot P, et al
    Response to the correspondence: "Non-optimal methodology questions indirect treatment comparison of dupilumab vs other biologics in severe asthma".
    Respir Med. 2022;191:106088.

  40. MARTIN N, Papi A, Bratton DJ, Chan R, et al
    Comment on: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma [Respir Med 2020].
    Respir Med. 2022;191:106065.

  41. BATEMAN ED, Khan AH, Xu Y, Guyot P, et al
    Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma.
    Respir Med. 2022;191:105991.
    PubMed     Abstract available

  42. SHEIKH D, Tripathi N, Chandler TR, Furmanek S, et al
    Clinical outcomes in patients with COPD hospitalized with SARS-CoV-2 versus non- SARS-CoV-2 community-acquired pneumonia.
    Respir Med. 2022;191:106714.
    PubMed     Abstract available

  43. BERGHAUS TM, Karschnia P, Haberl S, Schwaiblmair M, et al
    Disproportionate decline in admissions for exacerbated COPD during the COVID-19 pandemic.
    Respir Med. 2022;191:106120.

  44. MIR T, Uddin M, Khalil A, Lohia P, et al
    Mortality outcomes associated with invasive aspergillosis among acute exacerbation of chronic obstructive pulmonary disease patient population.
    Respir Med. 2022;191:106720.
    PubMed     Abstract available

  45. OBLING N, Rangelov B, Backer V, Hurst JR, et al
    Upper airway symptoms and Small Airways Disease in Chronic Obstructive Pulmonary Disease, COPD.
    Respir Med. 2022;191:106710.
    PubMed     Abstract available

  46. JALASTO J, Lassmann-Klee P, Schyllert C, Luukkonen R, et al
    Occupation, socioeconomic status and chronic obstructive respiratory diseases - The EpiLung study in Finland, Estonia and Sweden.
    Respir Med. 2022;191:106403.
    PubMed     Abstract available

  47. OBI ON, Judson MA, Birring SS, Maier LA, et al
    Assessment of dyspnea in sarcoidosis using the Baseline Dyspnea Index (BDI) and the Transition Dyspnea Index (TDI).
    Respir Med. 2022;191:106436.
    PubMed     Abstract available

  48. BATEMAN ED, Khan AH, Xu Y, Guyot P, et al
    Response to comment on: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma (Respir. Med. 2020).
    Respir Med. 2022;191:106106.

    December 2021
  49. TERPSTRA LC, Altenburg J, Mohamed Hoesein FA, Bronsveld I, et al
    The effect of maintenance azithromycin on radiological features in patients with bronchiectasis - Analysis from the BAT randomized controlled trial.
    Respir Med. 2021;192:106718.
    PubMed     Abstract available

  50. MONTEIRO C, Maricoto T, Prazeres F, Augusto Simoes P, et al
    Determining factors associated with inhaled therapy adherence on asthma and COPD: A systematic review and meta-analysis of the global literature.
    Respir Med. 2021;191:106724.
    PubMed     Abstract available

  51. WILGUS ML, Abtin F, Markovic D, Tashkin DP, et al
    Panlobular emphysema is associated with COPD disease severity: A study of emphysema subtype by computed tomography.
    Respir Med. 2021;192:106717.
    PubMed     Abstract available

  52. BARTOLI ML, Latorre M, Vagaggini B, Nieri D, et al
    Are sputum eosinophils associated with a different phenotype in COPD patients? A retrospective study.
    Respir Med. 2021;190:106672.
    PubMed     Abstract available

  53. PENG J, Wu F, Tian H, Yang H, et al
    Clinical characteristics of and risk factors for small airway dysfunction detected by impulse oscillometry.
    Respir Med. 2021;190:106681.
    PubMed     Abstract available

  54. MONGIARDO MA, Robinson SA, Finer EB, Cruz Rivera PN, et al
    The Effect of a web-based physical activity intervention on COPD knowledge: A secondary cohort study.
    Respir Med. 2021;190:106677.
    PubMed     Abstract available

  55. LEE CT, Chien JY, Hsu MJ, Wu HD, et al
    Inspiratory muscle activation during inspiratory muscle training in patients with COPD.
    Respir Med. 2021;190:106676.
    PubMed     Abstract available

  56. YAMAMOTO A, Nakamoto H, Yamaguchi T, Sakai H, et al
    Validity of a novel respiratory rate monitor comprising stretchable strain sensors during a 6-min walking test in patients with chronic pulmonary obstructive disease.
    Respir Med. 2021;190:106675.
    PubMed     Abstract available

  57. CAILLE P, Alexandre F, Molinier V, Heraud N, et al
    The role of personality traits in inpatient pulmonary rehabilitation response in patients with chronic obstructive pulmonary disease.
    Respir Med. 2021;190:106680.
    PubMed     Abstract available

  58. AL CHIKHANIE Y, Bailly S, Amroussia I, Veale D, et al
    Trajectories of COPD patients' response to repeated pulmonary rehabilitation programs.
    Respir Med. 2021;190:106678.
    PubMed     Abstract available

  59. IRINA BP, Steluta MM, Emanuela T, Diana M, et al
    Respiratory muscle training program supplemented by a cell-phone application in COPD patients with severe airflow limitation.
    Respir Med. 2021;190:106679.
    PubMed     Abstract available

    November 2021
  60. FAN Q, Ong ASE, Koh MS, Doshi K, et al
    The mediating role of trust in physician and self-efficacy in understanding medication adherence in severe asthma.
    Respir Med. 2021;190:106673.
    PubMed     Abstract available

  61. JEONG JS, Kim JS, You YS, Yeom SW, et al
    COPD is a risk factor for COVID-19, but does not confer increased severity of the disease.
    Respir Med. 2021;189:106640.
    PubMed     Abstract available

  62. SUISSA S, Dell'Aniello S, Ernst P
    Comparing initial LABA-ICS inhalers in COPD: Real-world effectiveness and safety.
    Respir Med. 2021;189:106645.
    PubMed     Abstract available

  63. PALM A, Ekstrom M
    Hypoxemia severity and survival in ILD and COPD on long-term oxygen therapy - The population-based DISCOVERY study.
    Respir Med. 2021;189:106659.
    PubMed     Abstract available

  64. DE BISSCHOP C, Caron F, Ingrand P, Bretonneau Q, et al
    Does branched-chain amino acid supplementation improve pulmonary rehabilitation effect in COPD?
    Respir Med. 2021;189:106642.
    PubMed     Abstract available

  65. KARIM A, Muhammad T, Ustrana S, Qaisar R, et al
    Intestinal permeability marker zonulin as a predictor of sarcopenia in chronic obstructive pulmonary disease.
    Respir Med. 2021;189:106662.
    PubMed     Abstract available

  66. OIE MR, Sue-Chu M, Helvik AS, Steinsvag SK, et al
    Rhinosinusitis without nasal polyps is associated with poorer health-related quality of life in COPD.
    Respir Med. 2021;189:106661.
    PubMed     Abstract available

  67. KUNUTSOR SK, Jae SY, Makikallio TH, Kurl S, et al
    High fitness levels offset the increased risk of chronic obstructive pulmonary disease due to low socioeconomic status: A cohort study.
    Respir Med. 2021;189:106647.
    PubMed     Abstract available

  68. AL-MOAMARY MS, Kokturk N, Idrees MM, Sen E, et al
    Unmet need in the management of chronic obstructive pulmonary disease in the Middle East and Africa region: An expert panel consensus.
    Respir Med. 2021;189:106641.
    PubMed     Abstract available

  69. IWAKURA M, Wakasa M, Okura K, Kawagoshi A, et al
    Functionally relevant threshold of inspiratory muscle strength in patients with chronic obstructive pulmonary disease.
    Respir Med. 2021;188:106625.
    PubMed     Abstract available

  70. AGGARWAL R, Lam AC, Huang J, Hueniken K, et al
    Stratification and management of patients ineligible for lung cancer screening.
    Respir Med. 2021;188:106610.
    PubMed     Abstract available

  71. ZAIGHAM S, Zhou X, Molin M, Sjolander A, et al
    Importance of type and degree of IgE sensitisation for defining fractional exhaled nitric oxide reference values.
    Respir Med. 2021;188:106621.
    PubMed     Abstract available

  72. HARTMAN JE, Conway F, Degano B, Augustijn SWS, et al
    Rate of lung function decline slows in the 3 years after targeted lung denervation in COPD.
    Respir Med. 2021;188:106604.

  73. KEMP R, Pustulka I, Boerner G, Smela B, et al
    Relationship between FEV1 decline and mortality in patients with bronchiolitis obliterans syndrome-a systematic literature review.
    Respir Med. 2021;188:106608.
    PubMed     Abstract available

    October 2021
  74. CZIRA A, Turner M, Martin A, Hinds D, et al
    A systematic literature review of burden of illness in adults with uncontrolled moderate/severe asthma.
    Respir Med. 2021;191:106670.
    PubMed     Abstract available

  75. ROGLIANI P, Ritondo BL, Puxeddu E, Cazzola M, et al
    Impact of long-acting muscarinic antagonists on small airways in asthma and COPD: A systematic review.
    Respir Med. 2021;189:106639.
    PubMed     Abstract available

  76. CHEN J, Weldemichael L, Zeng S, Giang B, et al
    Actigraphy informs distinct patient-centered outcomes in Pre-COPD.
    Respir Med. 2021;187:106543.
    PubMed     Abstract available

  77. RODRIGUEZ-GARCIA C, Blanco-Aparicio M, Nieto-Fontarigo JJ, Blanco-Cid N, et al
    Efficacy of mepolizumab in usual clinical practice and characteristics of responders.
    Respir Med. 2021;187:106595.
    PubMed     Abstract available

  78. AGUSTI A, Barnes N, Cruz AA, Gibson PG, et al
    Moving towards a Treatable Traits model of care for the management of obstructive airways diseases.
    Respir Med. 2021;187:106572.
    PubMed     Abstract available

  79. HOSKING L, Yeo A, Hoffman J, Chiano M, et al
    Genetics plays a limited role in predicting chronic obstructive pulmonary disease treatment response and exacerbation.
    Respir Med. 2021;187:106573.
    PubMed     Abstract available

  80. WAN ES, Goldstein RL, Garshick E, DeMeo DL, et al
    Molecular markers of aging, exercise capacity, & physical activity in COPD.
    Respir Med. 2021;187:106576.
    PubMed     Abstract available

  81. RIIKONEN R, Korppi M, Tormanen S, Koponen P, et al
    Risk factors for irreversible airway obstruction after infant bronchiolitis.
    Respir Med. 2021;187:106545.
    PubMed     Abstract available

    September 2021
  82. KAPUR N, Stroil-Salama E, Morgan L, Yerkovich S, et al
    Factors associated with "Frequent Exacerbator" phenotype in children with bronchiectasis: The first report on children from the Australian Bronchiectasis Registry.
    Respir Med. 2021;188:106627.
    PubMed     Abstract available

  83. DE BOER GM, Tramper-Stranders GA, Houweling L, van Zelst CM, et al
    Adult but not childhood onset asthma is associated with the metabolic syndrome, independent from body mass index.
    Respir Med. 2021;188:106603.
    PubMed     Abstract available

  84. ROGLIANI P, Beasley R, Cazzola M, Calzetta L, et al
    SMART for the treatment of asthma: A network meta-analysis of real-world evidence.
    Respir Med. 2021;188:106611.
    PubMed     Abstract available

  85. OLIVEIRA A, Quach S, Alsubheen S, Dasouki S, et al
    Rapid access rehabilitation after exacerbations of COPD - A qualitative study.
    Respir Med. 2021;186:106532.
    PubMed     Abstract available

  86. LEO F, Bannehr M, Valenta S, Lippeck M, et al
    Impact of a computerized physician order entry (CPOE)-based antibiotic stewardship intervention on the treatment duration for pneumonia and COPD exacerbations.
    Respir Med. 2021;186:106546.
    PubMed     Abstract available

  87. GAZOURIAN L, Regis SM, Pagura EJ, Price LL, et al
    Qualitative coronary artery calcification scores and risk of all cause, COPD and pneumonia hospital admission in a large CT lung cancer screening cohort.
    Respir Med. 2021;186:106540.
    PubMed     Abstract available

  88. NIKOLAOU V, Massaro S, Garn W, Fakhimi M, et al
    The cardiovascular phenotype of Chronic Obstructive Pulmonary Disease (COPD): Applying machine learning to the prediction of cardiovascular comorbidities.
    Respir Med. 2021;186:106528.
    PubMed     Abstract available

  89. CAMAC ER, Voelker H, Criner GJ
    Impact of COPD exacerbations leading to hospitalization on general and disease-specific quality of life.
    Respir Med. 2021;186:106526.
    PubMed     Abstract available

  90. LINDBERG A, Lindberg L, Sawalha S, Nilsson U, et al
    Large underreporting of COPD as cause of death-results from a population-based cohort study.
    Respir Med. 2021;186:106518.
    PubMed     Abstract available

    August 2021
  91. AL-AHMAD M, Nurkic J, Othman Y, Jusufovic E, et al
    Severe asthma in Kuwait population: Phenotype-based approach.
    Respir Med. 2021;187:106586.
    PubMed     Abstract available

  92. CAPSTICK TG, Azeez NF, Deakin G, Goddard A, et al
    Ward based inhaler technique service reduces exacerbations of asthma and COPD.
    Respir Med. 2021;187:106583.
    PubMed     Abstract available

  93. GAGNE M, Lam Shin Cheung J, Kouri A, FitzGerald JM, et al
    A patient decision aid for mild asthma: Navigating a new asthma treatment paradigm.
    Respir Med. 2021 Aug 10:106568. doi: 10.1016/j.rmed.2021.106568.
    PubMed     Abstract available

  94. SCHNEIDER CV, Strnad P
    SARS-CoV-2 infection in alpha1-antitrypsin deficiency.
    Respir Med. 2021;184:106466.
    PubMed     Abstract available

  95. VITACCA M, Ambrosino N, Belli S, Vigna M, et al
    The severity of acute exacerbations of COPD and the effectiveness of pulmonary rehabilitation.
    Respir Med. 2021;184:106465.
    PubMed     Abstract available

  96. GILLIAM EA, Kilgore KL, Liu Y, Bernier L, et al
    Managing the experience of breathlessness with Tai Chi: A qualitative analysis from a randomized controlled trial in COPD.
    Respir Med. 2021;184:106463.
    PubMed     Abstract available

  97. GUO C, Yu T, Chang LY, Bo Y, et al
    Mortality risk attributable to classification of chronic obstructive pulmonary disease and reduced lung function: A 21-year longitudinal cohort study.
    Respir Med. 2021;184:106471.
    PubMed     Abstract available

  98. METERAN H, Thomsen SF, Miller MR, Hjelmborg J, et al
    Impact of the spirometric definition on comorbidities in chronic obstructive pulmonary disease.
    Respir Med. 2021;184:106399.
    PubMed     Abstract available

  99. TAKEI N, Suzuki M, Tanabe N, Oguma A, et al
    Combined assessment of pulmonary arterial enlargement and coronary calcification predicts the prognosis of patients with chronic obstructive pulmonary disease.
    Respir Med. 2021;185:106520.
    PubMed     Abstract available

  100. CASTELLO-SIMOES V, Kabbach EZ, Schafauser NS, Camargo PF, et al
    Brain-heart autonomic axis across different clinical status and severity of chronic obstructive pulmonary disease.
    Respir Med. 2021;185:106511.
    PubMed     Abstract available

  101. CORLATEANU A, Plahotniuc A, Corlateanu O, Botnaru V, et al
    Multidimensional indices in the assessment of chronic obstructive pulmonary disease.
    Respir Med. 2021;185:106519.
    PubMed     Abstract available

  102. MARTINEZ FJ, Rabe KF, Ferguson GT, Wedzicha JA, et al
    Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial.
    Respir Med. 2021;185:106509.
    PubMed     Abstract available

  103. KELLERER C, Kahnert K, Trudzinski FC, Lutter J, et al
    COPD maintenance medication is linked to left atrial size: Results from the COSYCONET cohort.
    Respir Med. 2021;185:106461.
    PubMed     Abstract available

  104. PATHAK JL, Yan Y, Zhang Q, Wang L, et al
    The role of oral microbiome in respiratory health and diseases.
    Respir Med. 2021;185:106475.
    PubMed     Abstract available

  105. ANDRIANOPOULOS V, Gloeckl R, Schneeberger T, Jarosch I, et al
    Benefits of pulmonary rehabilitation in COPD patients with mild cognitive impairment - A pilot study.
    Respir Med. 2021;185:106478.
    PubMed     Abstract available

    July 2021
  106. WU J, Bracken J, Lam A, Francis KL, et al
    Refining diagnostic criteria for paediatric bronchiectasis using low-dose CT scan.
    Respir Med. 2021;187:106547.
    PubMed     Abstract available

  107. WAATEVIK M, Frisk B, Real FG, Hardie JA, et al
    CT-defined emphysema in COPD patients and risk for change in desaturation status in 6-min walk test.
    Respir Med. 2021;187:106542.
    PubMed     Abstract available

  108. VEDEL-KROGH S, Nielsen SF, Nordestgaard BG, Lange P, et al
    Asthma and COPD versus phenotypic traits: Toward precision medicine in chronic airway disease.
    Respir Med. 2021;186:106529.
    PubMed     Abstract available

    June 2021
  109. THI LAM H, Van Tuong N, Sy DQ, Lundback B, et al
    Bronchial hyperresponsiveness is common in Hanoi, Vietnam: Asthma probably underdiagnosed.
    Respir Med. 2021;186:106513.
    PubMed     Abstract available

  110. ZHANG M, Jin M, Zhou X, Lin J, et al
    Effectiveness of omalizumab in patients with severe allergic asthma: A retrospective study in China.
    Respir Med. 2021;186:106522.
    PubMed     Abstract available

  111. CHAPMAN KR, An L, Bosnic-Anticevich S, Campomanes CM, et al
    Asthma patients' and physicians' perspectives on the burden and management of asthma.
    Respir Med. 2021;186:106524.
    PubMed     Abstract available

  112. SCHYLLERT C, Andersson M, Backman H, Lindberg A, et al
    Childhood onset asthma is associated with lower educational level in young adults - A prospective cohort study.
    Respir Med. 2021;186:106514.
    PubMed     Abstract available

  113. YOUSIF A, Forget A, Beauchesne MF, Lemiere C, et al
    Development of an operational definition of treatment escalation in adults with asthma adapted to healthcare administrative databases: A Delphi study.
    Respir Med. 2021;185:106510.
    PubMed     Abstract available

  114. DUCHENE B, Caffry S, Kaminsky DA, Que LG, et al
    Functional significance of 8-isoprostanes in sinonasal disease and asthma.
    Respir Med. 2021;185:106506.
    PubMed     Abstract available

  115. RODRIGUES AT, Romano S, Romao M, Figueira D, et al
    Effectiveness of a pharmacist-led intervention on inhalation technique for asthma and COPD patients: The INSPIRA pilot cluster-randomized controlled trial.
    Respir Med. 2021;185:106507.
    PubMed     Abstract available

  116. JEONG JH, Heo M, Kim EJ, Hah YS, et al
    Serum hepatocyte growth factor as a predictor of disease severity and future exacerbations in patients with non-cystic fibrosis bronchiectasis.
    Respir Med. 2021;185:106505.
    PubMed     Abstract available

  117. GARCIA-PACHON E, Ruiz-Alcaraz S, Baeza-Martinez C, Zamora-Molina L, et al
    Symptoms in patients with asthma infected by SARS-CoV-2.
    Respir Med. 2021;185:106495.
    PubMed     Abstract available

  118. SHKEIRI R, Saliba W, Stein N, Najjar R, et al
    Exploring factors associated with acquisition and chronicity of infection in bronchiectasis: A population-based study.
    Respir Med. 2021;185:106487.
    PubMed     Abstract available

  119. SADEGHDOUST M, Mirsadraee M, Aligolighasemabadi F, Khakzad MR, et al
    Effect of azithromycin on bronchial wall thickness in severe persistent asthma: A double-blind placebo-controlled randomized clinical trial.
    Respir Med. 2021;185:106494.
    PubMed     Abstract available

  120. MANISCALCO M, Ambrosino P, Fuschillo S, Stufano S, et al
    Bronchodilator reversibility testing in post-COVID-19 patients undergoing pulmonary rehabilitation.
    Respir Med. 2021;182:106401.
    PubMed     Abstract available

  121. CRIMI C, Campisi R, Nolasco S, Cacopardo G, et al
    Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis: A real-world retrospective pilot study.
    Respir Med. 2021;185:106491.
    PubMed     Abstract available

  122. SHE W, Jia S, Hua Y, Feng X, et al
    The effect of nitrogen dioxide and atmospheric pressure on hospitalization risk for chronic obstructive pulmonary disease in Guangzhou, China.
    Respir Med. 2021;182:106424.
    PubMed     Abstract available

  123. CANTOR JO, Ma S, Liu X, Campos MA, et al
    A 28-day clinical trial of aerosolized hyaluronan in alpha-1 antiprotease deficiency COPD using desmosine as a surrogate marker for drug efficacy.
    Respir Med. 2021;182:106402.
    PubMed     Abstract available

  124. MARTH K, Renner A, Pohl W
    TRICOP - A Real-world effectiveness study with a single-inhaler extrafine triple therapy over 52 weeks in Austrian patients with COPD.
    Respir Med. 2021;182:106398.
    PubMed     Abstract available

  125. KRAEN M, Frantz S, Nihlen U, Engstrom G, et al
    Fibroblast growth factor 23 is an independent marker of COPD and is associated with impairment of pulmonary function and diffusing capacity.
    Respir Med. 2021;182:106404.
    PubMed     Abstract available

  126. KIM C, Ko Y, Lee JS, Rhee CK, et al
    Predicting long-term mortality with two different criteria of exercise-induced desaturation in COPD.
    Respir Med. 2021;182:106393.
    PubMed     Abstract available

  127. AMADO CA, Munoz P, Garcia-Unzueta M, Aguero J, et al
    High parathyroid hormone predicts exacerbations in COPD patients with hypovitaminosis D.
    Respir Med. 2021;182:106416.
    PubMed     Abstract available

  128. AL-QEREM WA, Jarab AS
    Applicability of GLI 2012 spirometry equation among preschool aged Jordanian.
    Respir Med. 2021;182:106397.
    PubMed     Abstract available

    May 2021
  129. ANDUJAR-ESPINOSA R, Aparicio-Vicente M, Ruiz-Lopez FJ, Salinero-Gonzalez L, et al
    Influence of vitamin D supplementation on the quality of life of asthma patients: Findings from ACVID randomised clinical trial.
    Respir Med. 2021;185:106484.
    PubMed     Abstract available

  130. LISSPERS K, Stallberg B, Larsson K, Janson C, et al
    Developing a short-term prediction model for asthma exacerbations from Swedish primary care patients' data using machine learning - Based on the ARCTIC study.
    Respir Med. 2021;185:106483.
    PubMed     Abstract available

  131. PUDDU PE, Menotti A, Kromhout D, Kafatos A, et al
    Chronic bronchitis in the 50-year follow-up of the European cohorts of the Seven Countries Study: prevalence, mortality and association with cardiovascular diseases.
    Respir Med. 2021;181:106385.
    PubMed     Abstract available

  132. VINCKEN S, Sylvia V, Daniel S, Thomas E, et al
    The role of FeNO in stable COPD patients with eosinophilic airway inflammation.
    Respir Med. 2021;181:106377.

  133. CORDOVA-RIVERA L, Gardiner PA, Gibson PG, Winkler EAH, et al
    Sedentary time in people with obstructive airway diseases.
    Respir Med. 2021;181:106367.
    PubMed     Abstract available

  134. HEUBEL AD, Kabbach EZ, Schafauser NS, Phillips SA, et al
    Noninvasive ventilation acutely improves endothelial function in exacerbated COPD patients.
    Respir Med. 2021;181:106389.
    PubMed     Abstract available

    April 2021
  135. PINI L, Giordani J, Gardini G, Concoreggi C, et al
    Emergency department admission and hospitalization for COPD exacerbation and particulate matter short-term exposure in Brescia, a highly polluted town in northern Italy.
    Respir Med. 2021;179:106334.
    PubMed     Abstract available

  136. YANGUI F, Touil A, Antit S, Zakhama L, et al
    COPD prevalence in smokers with stable ischemic heart disease: A cross-sectional study in Tunisia.
    Respir Med. 2021;179:106335.
    PubMed     Abstract available

  137. VERBERKT CA, van den Beuken-van Everdingen MHJ, Dirksen CD, Schols JMGA, et al
    Cost-effectiveness of sustained-release morphine for refractory breathlessness in COPD: A randomized clinical trial.
    Respir Med. 2021;179:106330.
    PubMed     Abstract available

  138. TIOTIU A, Ioan I, Poussel M, Schweitzer C, et al
    Comparative analysis between available challenge tests in the hyperventilation syndrome.
    Respir Med. 2021;179:106329.
    PubMed     Abstract available

  139. ARMSTRONG M, Hume E, McNeillie L, Chambers F, et al
    Behavioural modification interventions alongside pulmonary rehabilitation improve COPD patients' experiences of physical activity.
    Respir Med. 2021;180:106353.
    PubMed     Abstract available

  140. LAMMI MR, Ghonim MA, Johnson J, D'Aquin J, et al
    Acute effect of inhaled iloprost on exercise dynamic hyperinflation in COPD patients: A randomized crossover study.
    Respir Med. 2021;180:106354.
    PubMed     Abstract available

    March 2021
  141. YE L, Gao X, Tu C, Du C, et al
    Comparative analysis of effectiveness of asthma control test-guided treatment versus usual care in patients with asthma from China.
    Respir Med. 2021;182:106382.
    PubMed     Abstract available

  142. CHALITSIOS CV, Shaw DE, McKeever TM
    Corticosteroids and bone health in people with asthma: A systematic review and meta-analysis.
    Respir Med. 2021;181:106374.
    PubMed     Abstract available

  143. SAFAVI S, Munidasa S, Zanette B, Dai R, et al
    Evaluating post-bronchodilator response in well-controlled paediatric severe asthma using hyperpolarised 129Xe-MRI: A pilot study.
    Respir Med. 2021;180:106368.
    PubMed     Abstract available

  144. LEE JM, Lee SA, Han CH, Lee SM, et al
    Body mass index as a predictor of mortality in bronchiectasis: A nationwide population-based study.
    Respir Med. 2021;180:106370.
    PubMed     Abstract available

  145. KAGOHASHI K, Miyazaki K, Satoh H
    Outcome of SARS-CoV-2 infection in patients with severe asthma on biologics.
    Respir Med. 2021 Mar 6:106358. doi: 10.1016/j.rmed.2021.106358.

  146. MENDY A, Wu X, Keller JL, Fassler CS, et al
    Long-term exposure to fine particulate matter and hospitalization in COVID-19 patients.
    Respir Med. 2021;178:106313.
    PubMed     Abstract available

  147. TURAN PA, Turan O, Guldaval F, Anar C, et al
    Transitions between COPD groups: A cross-sectional study in Turkey.
    Respir Med. 2021;178:106310.
    PubMed     Abstract available

    February 2021
  148. HAN DW, Jo KW, Kim OH, Shim TS, et al
    Cavity formation and its predictors in noncavitary nodular bronchiectatic Mycobacterium avium complex pulmonary disease.
    Respir Med. 2021;179:106340.
    PubMed     Abstract available

  149. UNNI EJ, Gupta S, Sternbach N
    Using the Medication Adherence Reasons Scale (MAR-Scale) in asthma and chronic obstructive pulmonary disease to determine the extent and identify the reasons for non-adherence.
    Respir Med. 2021;179:106337.
    PubMed     Abstract available

    January 2021
  150. SCOSYREV E, van Zyl-Smit R, Kerstjens H, Gessner C, et al
    Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials.
    Respir Med. 2021;180:106311.
    PubMed     Abstract available

  151. SOL IS, Jang H, Noh J, Kim SY, et al
    Mortality and morbidity in children with asthma: A nationwide study in Korea.
    Respir Med. 2021;177:106306.
    PubMed     Abstract available

  152. LIAO SY, Petrache I, Fingerlin TE, Maier LA, et al
    Association of inhaled and systemic corticosteroid use with Coronavirus Disease 2019 (COVID-19) test positivity in patients with chronic pulmonary diseases.
    Respir Med. 2021;176:106275.
    PubMed     Abstract available

  153. CAZZOLA M, Ora J, Bianco A, Rogliani P, et al
    Guidance on nebulization during the current COVID-19 pandemic.
    Respir Med. 2021;176:106236.
    PubMed     Abstract available

  154. HOESTEREY D, Graham B, Tashkin DP, Barjaktarevic I, et al
    Mid-expiratory time as a potential spirometric index of early airflow obstruction.
    Respir Med. 2021;176:105977.

  155. BROWN LK, Miller A
    Spirometric indices of early airflow impairment in individuals at risk of developing COPD: Spirometry beyond FEV1/FVC.
    Respir Med. 2021;176:105921.

  156. BACKMAN BH, Virchow JC, Lundback B
    COPD in women - New results presented.
    Respir Med. 2021;176:106238.

  157. ZELL-BARAN LM, Krefft SD, Moore CM, Wolff J, et al
    Multiple breath washout: A noninvasive tool for identifying lung disease in symptomatic military deployers.
    Respir Med. 2021;176:106281.
    PubMed     Abstract available

  158. OLIVEIRA CC, Annoni R, Lee AL, McGinley J, et al
    Falls prevalence and risk factors in people with chronic obstructive pulmonary disease: A systematic review.
    Respir Med. 2021;176:106284.
    PubMed     Abstract available

  159. LOPEZ-PINTOR E, Grau J, Gonzalez I, Bernal-Soriano MC, et al
    Impact of patients' perception of COPD and treatment on adherence and health-related quality of life in real-world: Study in 53 community pharmacies.
    Respir Med. 2021;176:106280.
    PubMed     Abstract available

  160. BAHA A, Kokturk N
    Physician's attitude against COPD guidelines and the choice of first-line treatment for COPD.
    Respir Med. 2021;176:106273.
    PubMed     Abstract available

  161. BJERRUM AS, Skjold T, Schmid JM
    Oral corticosteroid sparing effects of anti-IL5/ anti-IL5 receptor treatment after 2 years of treatment.
    Respir Med. 2021;176:106260.
    PubMed     Abstract available

  162. FRANCE G, Orme MW, Greening NJ, Steiner MC, et al
    Cognitive function following pulmonary rehabilitation and post-discharge recovery from exacerbation in people with COPD.
    Respir Med. 2021;176:106249.
    PubMed     Abstract available

  163. KEOGH E, Mark Williams E
    Managing malnutrition in COPD: A review.
    Respir Med. 2021;176:106248.
    PubMed     Abstract available

  164. ZAIGHAM S, Dencker M, Karlsson MK, Thorsson O, et al
    Lung function is associated with tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in school-aged children.
    Respir Med. 2021;176:106235.
    PubMed     Abstract available

  165. KOHLBRENNER D, Clarenbach CF, Thiel S, Roeder M, et al
    A few more steps lead to improvements in endothelial function in severe and very severe COPD.
    Respir Med. 2021;176:106246.
    PubMed     Abstract available

    December 2020
  166. CHOATE R, Aksamit TR, Mannino D, Addrizzo-Harris D, et al
    Pseudomonas aeruginosa associated with severity of non-cystic fibrosis bronchiectasis measured by the modified bronchiectasis severity score (BSI) and the FACED: The US bronchiectasis and NTM Research Registry (BRR) study.
    Respir Med. 2020;177:106285.
    PubMed     Abstract available

  167. EGER K, Hashimoto S, Braunstahl GJ, Brinke AT, et al
    Poor outcome of SARS-CoV-2 infection in patients with severe asthma on biologic therapy.
    Respir Med. 2020;177:106287.
    PubMed     Abstract available

  168. SANGIOVANNI S, Morales EI, Fernandez-Trujillo L
    Inhaled tobramycin for chronic infection with pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis.
    Respir Med. 2020;176:106283.
    PubMed     Abstract available

  169. LIU Y, Huang X, Chen D, Chen F, et al
    The detrimental qualitative and quantitative alterations of circulating endothelial progenitor cells in patients with bronchiectasis.
    Respir Med. 2020;176:106270.
    PubMed     Abstract available

    November 2020
  170. KUPCZYK M, Majak P, Kuna P, Asankowicz-Bargiel B, et al
    A new formulation of fluticasone propionate/salmeterol in a metered-dose inhaler (MDI HFA) allows for the reduction of a daily dose of corticosteroid and provides optimal asthma control - A randomized, multi-center, non-inferiority, phase IV clinical
    Respir Med. 2020;176:106274.
    PubMed     Abstract available

  171. TERVONEN T, Martinez FJ, Hanania NA, Heidenreich S, et al
    Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment.
    Respir Med. 2020;176:106278.
    PubMed     Abstract available

  172. PULLERITS T, Ronmark EP, Ekerljung L, Palmqvist MA, et al
    The triad of current asthma, rhinitis and eczema is uncommon among adults: Prevalence, sensitization profiles, and risk factors.
    Respir Med. 2020;176:106250.
    PubMed     Abstract available

  173. CAMINATI M, Vultaggio A, Matucci A, Senna G, et al
    Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity.
    Respir Med. 2020;176:106261.
    PubMed     Abstract available

  174. BASSAM M, Behbehani N, Farouk H, Alsayed M, et al
    Adherence to medication among adult asthma patients in the Middle East and North Africa: results from the ESMAA study.
    Respir Med. 2020;176:106244.
    PubMed     Abstract available

  175. GAZOURIAN L, Thedinger WB, Regis SM, Pagura EJ, et al
    Qualitative emphysema and risk of COPD hospitalization in a multicenter CT lung cancer screening cohort study.
    Respir Med. 2020;176:106245.
    PubMed     Abstract available

  176. COTTINI M, Licini A, Lombardi C, Berti A, et al
    Prevalence and features of IOS-defined small airway disease across asthma severities.
    Respir Med. 2020;176:106243.
    PubMed     Abstract available

  177. LOMMATZSCH M, Sauerbeck IS, Wilmer C, Taube C, et al
    Oral corticosteroid prescription for asthma by general practitioners: A three-year analysis in Germany.
    Respir Med. 2020;176:106242.
    PubMed     Abstract available

  178. HUSSEIN MH, Toraih EA, Attia AS, Burley N, et al
    Asthma in COVID-19 patients: An extra chain fitting around the neck?
    Respir Med. 2020;175:106205.
    PubMed     Abstract available

  179. GRAFF S, Bricmont N, Moermans C, Henket M, et al
    Clinical and biological factors associated with irreversible airway obstruction in adult asthma.
    Respir Med. 2020;175:106202.
    PubMed     Abstract available

  180. MOHR A, Plentz A, Sieroslawski A, Pezenburg F, et al
    Use of Pneumococcal and influenza vaccine in patients with COPD, asthma bronchiale and interstitial lung diseases in south east Germany.
    Respir Med. 2020;174:106207.
    PubMed     Abstract available

  181. FEDDEMA JJ, Claassen E
    Prevalence of viral respiratory infections amongst asthmatics: Results of a meta-regression analysis.
    Respir Med. 2020;173:106020.
    PubMed     Abstract available

  182. RAISANEN P, Hedman L, Andersson M, Stridsman C, et al
    Non-response did not affect prevalence estimates of asthma and respiratory symptoms - results from a postal questionnaire survey of the general population.
    Respir Med. 2020;173:106017.
    PubMed     Abstract available

    October 2020
  183. QIN L, Li Z, Fan Y, Fang X, et al
    Exploration of plasma interleukin-27 levels in asthma patients and the correlation with lung function.
    Respir Med. 2020;175:106208.
    PubMed     Abstract available

  184. PAOLETTI G, Keber E, Heffler E, Malipiero G, et al
    Effect of an educational intervention delivered by pharmacists on adherence to treatment, disease control and lung function in patients with asthma.
    Respir Med. 2020;174:106199.
    PubMed     Abstract available

  185. GESSNER C, Kornmann O, Maspero J, van Zyl-Smit R, et al
    Corrigendum to "Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority stu
    Respir Med. 2020 Oct 17:106186. doi: 10.1016/j.rmed.2020.106186.

  186. LITT HK, Press VG, Hull A, Siros M, et al
    Association between inhaler technique and confidence among hospitalized children with asthma.
    Respir Med. 2020;174:106191.
    PubMed     Abstract available

  187. MORILLO-VANEGAS D, Sanchez-Salcedo P, Sebastian Arino AF
    Relationship between pediatric asthma and psychosocial status of caregivers.
    Respir Med. 2020;174:106187.
    PubMed     Abstract available

    September 2020
  188. LASSMANN-KLEE PG, Piirila PL, Brumpton B, Larsson M, et al
    Parallel gradients in FENO and in the prevalences of asthma and atopy in adult general populations of Sweden, Finland and Estonia - A Nordic EpiLung study.
    Respir Med. 2020;173:106160.
    PubMed     Abstract available

  189. BUSBY J, Khoo E, Pfeffer PE, Mansur AH, et al
    The effects of oral corticosteroids on lung function, type-2 biomarkers and patient-reported outcomes in stable asthma: A systematic review and meta-analysis.
    Respir Med. 2020;173:106156.
    PubMed     Abstract available

  190. FOSTER JM, Beasley R, Braithwaite I, Harrison T, et al
    Patient experiences of as-needed budesonide-formoterol by Turbuhaler(R) for treatment of mild asthma; a qualitative study.
    Respir Med. 2020;175:106154.
    PubMed     Abstract available

  191. CHAN KPF, Ma TF, Kwok WC, Leung JKC, et al
    Significant reduction in hospital admissions for acute exacerbation of chronic obstructive pulmonary disease in Hong Kong during coronavirus disease 2019 pandemic.
    Respir Med. 2020;171:106085.
    PubMed     Abstract available

    Underlying respiratory diseases, specifically COPD, and smoking are associated with severe COVID-19 outcomes: A systematic review and meta-analysis.
    Respir Med. 2020;171:106096.
    PubMed     Abstract available

    August 2020
  193. OUAALAYA EH, Falque L, Dupis JM, Sabatini M, et al
    Susceptibility to frequent exacerbation in COPD patients: Impact of the exacerbations history, vaccinations and comorbidities?
    Respir Med. 2020;169:106018.
    PubMed     Abstract available

  194. ARO M, Saaresranta T, Vahlberg T, Anttalainen U, et al
    Medication of comorbidities in females with sleep-disordered breathing during long-term CPAP therapy.
    Respir Med. 2020;169:106014.
    PubMed     Abstract available

    June 2020
  195. JONES TPW, Brown J, Hurst JR, Vancheeswaran R, et al
    COPD exacerbation phenotypes in a real-world five year hospitalisation cohort.
    Respir Med. 2020;167:105979.
    PubMed     Abstract available

    May 2020
  196. SHIRAI T, Furuuchi K, Fujiwara K, Nakamoto K, et al
    Impact of Aspergillus precipitating antibody test results on clinical outcomes of patients with Mycobacterium avium complex lung disease.
    Respir Med. 2020;166:105955.
    PubMed     Abstract available

  197. LARSSON-CALLERFELT AK, Muller C, Andersson-Sjoland A, Thiman L, et al
    VEGF synthesis and VEGF receptor 2 expression in patients with bronchiolitis obliterans syndrome after lung transplantation.
    Respir Med. 2020;166:105944.
    PubMed     Abstract available

  198. BEZERRA DE MENEZES M, Ponte EV, Bertagni Mingotti CF, Carvalho Pinto RM, et al
    Provision of inhaled corticosteroids is associated with decrease in hospital admissions in Brazil: A longitudinal nationwide study.
    Respir Med. 2020;166:105950.
    PubMed     Abstract available

  199. VOGELMEIER CF, Roman-Rodriguez M, Singh D, Han MK, et al
    Goals of COPD treatment: Focus on symptoms and exacerbations.
    Respir Med. 2020;166:105938.
    PubMed     Abstract available

    April 2020
  200. FASTENAU A, van Schayck OC, Winkens B, Aretz K, et al
    Effectiveness of an exercise training programme COPD in primary care: A randomized controlled trial.
    Respir Med. 2020;165:105943.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Obstructive Lung Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.